Market Overview

Benzinga's Top Pre-Market Losers

Share:
Related RIGL
Benzinga's Top Upgrades, Downgrades For December 15, 2017
Benzinga's Top Upgrades, Downgrades For November 6, 2017
Related AZN
Here's Why Nektar Stock Skyrocketed Almost 500% In A Year
Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says
Biotech Analysis Central Pharma News: Novartis's Speedy Review, Aeterna's Surprise Sell, Aveo's Advance In Liver Cancer (Seeking Alpha)

Rigel Pharmaceuticals (NASDAQ: RIGL) shares fell 17.44% to $3.74 in the pre-market trading after the company and AstraZeneca (NYSE: AZN) announced topline results from OSKIRA-2 and OSKIRA-3.

Dollar General (NYSE: DG) dipped 5.36% to $50.68 in the pre-market session. Dollar General reported a 3% rise in its first-quarter profit.

salesforce.com (NYSE: CRM) shares dropped 3.24% to $39.71 in pre-market trading after the company announced its plans to buy ExactTarget (NYSE: ET) for $2.34 billion.

Biogen Idec (NASDAQ: BIIB) dipped 2.36% to $222.02 in the pre-market session. Biogen Idec's trailing-twelve-month ROA is 12.81%.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (BIIB + AZN)

View Comments and Join the Discussion!